Dupilumab: Clinical & Economic Profile

Analysis of dosing intensity, safety ranges, and pharmacokinetic efficiency across indications

Design Drug Monograph Review Population Adults & Pediatrics (various indications) N Aggregated Duration Indefinite (Maintenance) Comparator Standard of Care / Placebo (historical) Year 2024

Key Performance Indicators

PRIMARY

Max Bioavailability

64%

Range: 61–64%

High subcutaneous absorption

Max Washout Period

13 weeks

For 300mg weekly dosing

Time to non-detectable levels

Top Adverse Event

38%

Injection-site reactions

Upper limit of reported incidence

Cost Per Dose (US)

~$2,282

Calculated from AWP/mL

Flat pricing across strengths

01

Eosinophilic Esophagitis Requires the Most Intensive Maintenance Dosing

While Asthma and Atopic Dermatitis are maintained on a bi-weekly schedule, EoE requires weekly administration.

02

Injection Site Reactions and Immunogenicity Show Widest Variability

Adverse event rates vary significantly, with injection site reactions ranging from 6% to 38%.

03

Drug Clearance Time is Dose-Frequency Dependent

Weekly dosing leads to significantly longer washout periods (13 weeks) compared to bi-weekly regimens.

04

Subcutaneous Bioavailability is Robust

The drug achieves over 60% bioavailability via subcutaneous injection.

05

Pricing Strategy: Higher Concentration Offsets Lower Volume Cost

While the 200mg/1.14mL formulation is nearly double the price per mL of the 300mg/2mL, the total dose cost remains identical (~$2,282).

06

Volume of Distribution Indicates Limited Tissue Penetration

The volume of distribution (4.8 L) approximates human blood volume, suggesting the drug remains largely in the vascular space.

Editorial Conclusion

“Dupilumab demonstrates a versatile efficacy profile across Type 2 inflammatory diseases with a safety profile dominated by local injection reactions and respiratory infections.”

Dosing intensity varies by indication, with EoE requiring the highest frequency (weekly).

Pharmacokinetics show dose-dependent clearance ranging from 9 to 13 weeks.

Pricing is structured to neutralize cost differences between dose strengths.

Clinical Implication

Clinicians must tailor monitoring for ocular and respiratory adverse events based on the specific indication and dosing frequency.

Reference Data & Sources

Complete Data Table

viz_id	chart_type	label	group	value	value_text	low	high	sd	unit	category	target
viz1	horizontal_bar	Eosinophilic Esophagitis	Maintenance Interval	7					Days	High Intensity
viz1	horizontal_bar	Atopic Dermatitis	Maintenance Interval	14					Days	Standard Intensity
viz1	horizontal_bar	Asthma	Maintenance Interval	14					Days	Standard Intensity
viz1	horizontal_bar	Rhinosinusitis (Nasal Polyps)	Maintenance Interval	14					Days	Standard Intensity
viz2	range_plot	Injection-site reaction	Local	22		6	38		%
viz2	range_plot	Antibody development	Immunologic	8.5		1	16		%
viz2	range_plot	Conjunctivitis	Ophthalmic	5			10		%
viz2	range_plot	Upper Resp. Infection	Respiratory	18		18	18		%
viz2	range_plot	Nasopharyngitis	Respiratory	5		5	5		%
viz3	dot_strip	300 mg Weekly	High Frequency	13					Weeks	Clearance Time
viz3	dot_strip	300 mg Every 2 Weeks	Standard Frequency	10.5					Weeks	Clearance Time
viz3	dot_strip	200 mg Every 2 Weeks	Low Dose Standard	9					Weeks	Clearance Time
viz4	gauge	Bioavailability	Pharmacokinetics	64		61	64		%		100
viz5	dumbbell	200 mg / 1.14 mL	Price per mL (AWP)	2001.68	$2,001/mL					Cost
viz5	dumbbell	300 mg / 2 mL	Price per mL (AWP)	1140.96	$1,141/mL					Cost
viz6	forest	Volume of Distribution (Vd)	Adults	4.8		3.5	6.1	1.3	L

Abbreviations

Abbrev	Meaning
AWP	Average Wholesale Price
EoE	Eosinophilic Esophagitis
SUBQ	Subcutaneous
Vd	Volume of Distribution

Source

UpToDate, Topic 112484 Version 194.0

Limitations

Pricing data is based on AWP and may not reflect actual acquisition costs.
Adverse event rates are aggregated from labeling and may vary by specific patient population.